Immunization Products Limited
Elizabeth Corsi appointed VP and general manager of the newly- formed operational unit for the Rhone-Poulenc Rorer/Immune Response Corp. joint venture for an AIDS vaccine. Results of Phase II/III trials of the AIDS immunotherapeutic (the "Salk vaccine") are now being compiled and should be unblinded by early next year. A PLA will be filed in 1993 if the results are positive. Production capacities are being scaled up for commercial production of the vaccine.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth